INTENSITY THERAPEUTICS, INC. Material Event: An Analyst's View

INTENSITY THERAPEUTICS, INC. recently announced a significant corporate action: a reverse stock split. This summary explains what happened, why it matters, and what investors should consider regarding this development.

---

Event Description

INTENSITY THERAPEUTICS, INC. has announced a 1-for-25 reverse stock split of its common stock. This means that for every 25 shares an investor currently owns, they will receive one new share. The company's Board of Directors and shareholders approved this action, which involves an amendment to its Certificate of Incorporation.

Companies typically implement a reverse stock split when their stock price has significantly declined, often falling below specific price levels. For companies listed on Nasdaq, a critical rule (Nasdaq Listing Rule 5550(a)(2)) requires maintaining a minimum bid price of $1.00 per share. If a company's stock trades below this threshold for an extended period, it risks losing its listing on the exchange.

INTENSITY THERAPEUTICS is undertaking this reverse split primarily to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting. Beyond compliance, companies often pursue additional goals such as:

• Improving the stock's marketability.
• Making it more attractive to institutional investors, who often have policies against investing in "penny stocks."
• Enhancing its appeal for potential future capital raises.

This move often follows a period of sustained stock price decline, typically driven by factors common to clinical-stage biotechnology companies like INTENSITY THERAPEUTICS. These can include clinical trial setbacks, slower-than-expected progress in drug development, or challenges in securing adequate funding. While the 8-K filing does not detail the specific reasons for the stock's decline, investors should understand the underlying operational or financial challenges that led to this situation.

Event Date/Timeline

• Official Filing: The company officially filed the news with the SEC via an 8-K on February 13, 2026.
• Effective Date: The reverse stock split will become effective at 4:01 p.m. Eastern Time on February 18, 2026.
• New Trading Basis: Shares are expected to begin trading on The Nasdaq Capital Market on this new, post-split basis at the open of trading on February 19, 2026, under the existing ticker symbol "INTS."

Impact Assessment

• Share Count & Value for Investors: If you owned 25 shares at, for example, $0.50 each (total value $12.50), after the 1-for-25 split, you would own 1 share theoretically worth $12.50. The total dollar value of your investment initially remains the same, but your share count decreases significantly, and the price per share increases proportionally.
• Market Perception (A "Red Flag"): While necessary for Nasdaq compliance, the market often views reverse stock splits as a "red flag." This signals that a company has struggled to maintain its stock price and may face significant underlying business challenges. A reverse split does not inherently solve the operational or financial issues that caused the stock price to fall.
• Risk of Further Decline: The split itself does not guarantee a sustained higher stock price. If the company's fundamental business performance does not improve, the stock price could continue to decline post-split, potentially falling back below Nasdaq's minimum bid price requirement. This scenario, especially if combined with certain dilutive financing methods, is sometimes referred to as a "death spiral."
• Access to Capital: While maintaining a Nasdaq listing can help preserve access to capital markets, it does not guarantee successful fundraising if the company's clinical pipeline or financial health is not compelling to investors.

Financial Impact

The 1-for-25 reverse stock split will directly adjust the company's capital structure.

• Authorized Shares: The amendment to the Certificate of Incorporation typically includes a change to the number of authorized shares of common stock. However, the 8-K filing doesn't specify the new number of authorized shares.
• Par Value: Similarly, the 8-K doesn't mention if the par value per share of common stock will be adjusted, or what the new value would be.
• Shares Outstanding: The company will proportionately reduce the total number of common shares outstanding by a factor of 25. For example, if 250 million shares were outstanding before the split, approximately 10 million shares would be outstanding immediately after. The 8-K filing doesn't explicitly state the exact number of shares outstanding immediately after the split.
• Market Capitalization: The company's total market capitalization is not directly affected by the reverse stock split itself, as the increase in share price is intended to offset the decrease in the number of shares.
• Fractional Shares: If you own a number of shares that is not a multiple of 25 (e.g., 30 shares), you would end up with a fractional share (e.g., 1.2 shares). Instead of issuing a fraction of a share, the company will pay you cash for that fractional part, based on the common stock's closing price on the reverse split's effective date.
• Equity Plans: The company will also proportionally adjust the number of shares and exercise prices for outstanding stock options, warrants, and other equity awards for employees and executives to reflect the new share count.
• Dilution Risk: Reverse splits can sometimes precede new capital raises. While the split itself is not dilutive, a higher share price might make it easier for the company to issue new shares to raise funds. Depending on the terms, such future financing could still dilute existing shareholders.

Key Takeaways for Investors

The success of this reverse stock split, beyond merely maintaining a Nasdaq listing, depends entirely on INTENSITY THERAPEUTICS' ability to execute its core strategy and improve its underlying business performance. As a clinical-stage biotechnology company, this means:

• Advancing its Clinical Pipeline: Investors should closely monitor progress on its lead drug candidates (e.g., IT-01, if applicable) through various clinical trial phases. Positive data readouts and successful progression through regulatory hurdles are critical.
• Achieving Key Milestones: Look for specific announcements regarding clinical trial enrollment, interim data, final results, and regulatory submissions (e.g., FDA approvals).
• Securing Funding: The company will need sufficient capital to fund its research and development efforts. This could come from new equity offerings, debt financing, or strategic partnerships. Investors should assess the company's cash runway and burn rate from its financial statements.
• Potential Partnerships: Strategic collaborations with larger pharmaceutical companies could provide non-dilutive funding and validate their technology.
• Focus Beyond Price: A higher share price post-split does not mean the company is fundamentally stronger. Investors should focus on the underlying business.
• Dive into Financials: Review INTENSITY THERAPEUTICS' latest quarterly (10-Q) and annual (10-K) reports. Pay close attention to their cash and cash equivalents, operating expenses (burn rate), and projected cash runway. This is critical for understanding their ability to fund operations.
• Understand the Clinical Pipeline: Research their specific drug candidates, the diseases they target, their current stage of development, and expected upcoming catalysts (e.g., clinical trial results, regulatory decisions). Biotech investing is heavily driven by clinical success.
• Assess Management's Strategy: Look for clear communication from management about their plan to achieve clinical success, secure necessary funding, and ultimately bring their therapies to market.
• High-Risk Investment: Small-cap biotechnology companies, especially those resorting to reverse stock splits, carry significant risk. Clinical trials can fail, regulatory approvals are uncertain, and funding can be challenging. Diversification and a thorough understanding of these risks are paramount.